Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 29, 2025
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 30, 2021
Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Transplantation and cellular therapy
Published: November 05, 2020
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD.
Journal: Bone marrow transplantation
Published: August 22, 2020
Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients.
Journal: Transplant infectious disease : an official journal of the Transplantation Society
Published: April 16, 2020
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: January 17, 2020
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Journal: The Lancet. Haematology
Published: July 19, 2018
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
Journal: Bone marrow transplantation
Published: March 23, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: December 06, 2017
Stem Cell Transplantation and Informatics: Current Considerations.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: October 25, 2017
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Journal: The Lancet. Haematology
Published: December 06, 2016
Last Updated: 09/26/2026